BioNotebook: Controversial StemCells board appointment; Portola/Daiichi Sankyo, Lexicon/JDRF, Supernus; and stock offerings
This article was originally published in Scrip
Executive Summary
StemCells appoints former CIRM president; Daiichi Sankyo, Portola collaborate with Factor Xa inhibitor; Lexicon, JDRF partner on Phase II study; Supernus signs royalty deal; and Bluebird, Ultragenyx, Auspex and Ocera price offerings.